AUTHORS
Kai Dou, PhD, Qiao Jin, PhD2, Bojing Shao, PhD3, Ying Liang, MD, PhD4, Xiuli An Sr, MD, PhD5, Cheryl Lobo, PhD6, Karina Yazdanbakhsh, PhD7, Hui Zhong, MD, PhD8
AFFILIATIONS
1 LFKRI, New York Blood Center, Rye, New York, United States
2 LFKRI, New York Blood Center, Rye, New York, United States
3 LFKRI, New York Blood Center, Rye, New York, United States
4 LFKRI, New York Blood Center, Rye, New York, United States
5 LFKRI, New York Blood Center, Rye, New York, United States
6 LFKRI, New York Blood Center, Rye, New York, United States
7 LFKRI, New York Blood Center, Rye, New York, United States
8 LFKRI, New York Blood Center, Rye, New York, United States
ABSTRACT
Sickle cell disease (SCD) is characterized by chronic hemolysis and systemic inflammation, largely driven by free hemin released during intravascular hemolysis. Despite substantial therapeutic advances, affordable anti-inflammatory treatments remain an unmet need, particularly in resource-limited settings. We investigated whether hemin-binding antimalarial drugs can be repurposed as anti-inflammatory agents for SCD.
We first examined the effects of quinine and chloroquine (CQ) on hemin-induced cytokine production in human primary monocytes from healthy subjects. Incubating monocytes with hemin (25µM) induced IL-1β, TNF-α, and MCP-1 production. Preincubating hemin with either drug (0-25µM) dose-dependently reduced hemin-induced production of IL-1β, IL-6, TNF-α, and MCP-1. Quinine and CQ were comparably effective against IL-6 and TNF-α, but quinine inhibited IL-1β and MCP-1 8.3-fold and 4-fold more potently, respectively.
We next tested quinine or CQ in Townes SCD and control (AA) mice at 1.25 mg/kg/day in drinking water, well below the ~20 mg/kg used for malaria treatment. Quinine significantly reduced plasma TNF-α in SCD mice but had no effect in controls, suggesting a disease-specific anti-inflammatory effect. CQ did not alter cytokine levels in SCD mice or control mice.
We then examined quinine and CQ in a vaso-occlusive episode (VOE) model, with VOE the most common inflammatory complication of SCD. Mice received drinking water supplemented with 1.25 mg/kg/day or normal drinking water for 1 week before VOE induction with TNF-α (500 ng/mouse, intraperitoneally). Consistent with previous reports, TNF-α exacerbated anemia, caused liver injury, promoted hepatic vascular occlusion, and increased plasma MCP-1, TNF-α, IL-6, and IL-1β in SCD mice. Control AA mice also showed significant increases in plasma MCP-1, TNF-α, and IL-6 but did not develop anemia, liver injury, or vascular occlusion after TNF-α treatment. Quinine markedly attenuated TNF-α–induced anemia, reduced plasma ALT and AST levels, and decreased hepatic vascular occlusion. Quinine also suppressed plasma MCP-1, TNF-α, and IL-1β levels, whereas IL-6 was unaffected, indicating selective modulation of inflammatory pathways. Notably, quinine inhibited no cytokines in control mice, further supporting a disease-specific effect, and CQ failed to suppress cytokines or improve any VOE parameters.
We hypothesized that quinine acts by forming an anti-inflammatory complex with free hemin. We premixed hemin with quinine or CQ to form a quinine-hemin complex (QHC) or a CQ-hemin complex. Focusing on NLRP3 inflammasome priming and activation, QHC inhibited LPS priming-induced production of pro-IL-1β, IL-6, and TNF-α in healthy human monocytes (IC50 ~2.5 µM) and, more potently, suppressed IL-1β production induced by NLRP3 inflammasome agonists (IC50 ~0.6 µM). QHC also blocked NLRP3 inflammasome activation-induced pyroptosis and the maturation of GSDMD and pro–IL-1β, thereby identifying it as a potent inflammasome inhibitor. The CQ–hemin complex had no effect on NLRP3 inflammasome activation.
To define the structural basis of this activity, we screened 11 hemin-binding compounds for their ability to inhibit NLRP3-dependent IL-1β production. Halofantrine (HF) and mefloquine strongly inhibited IL-1β secretion, but only when premixed with hemin. Structure–activity analysis showed that all active compounds share a hydroxyl group on the carbon directly attached to the aromatic ring system. An HF analog in which this hydroxyl was replaced by an amino group, yielding a CQ-like structure, failed to inhibit IL-1β production with or without hemin, establishing the carbinol hydroxyl as essential.
These findings identify a therapeutic strategy that converts proinflammatory hemin into an anti-inflammatory entity and support the development of quinine-based compounds as accessible treatments for SCD and hemolysis-associated inflammation.
DISCLOSURES
Hui Zhong, MD, PhD: No relevant conflicts of interest to declare.